132 related articles for article (PubMed ID: 36550212)
1. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters.
Bruch PM; Dietrich S; Finel H; Boumendil A; Greinix H; Heinicke T; Bethge W; Beelen D; Schmid C; Martin H; Castagna L; Scheid C; Schäfer-Eckart K; Bittenbring J; Finke J; Sengeloev H; Heiblig M; Cornelissen J; Chevallier P; Mohty M; Robinson S; Montoto S; Dreger P
Leukemia; 2023 Feb; 37(2):465-472. PubMed ID: 36550212
[TBL] [Abstract][Full Text] [Related]
2. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Murthy HS; Zhang MJ; Chen K; Ahmed S; Deotare U; Ganguly S; Kansagra A; Michelis FV; Nishihori T; Patnaik M; Abid MB; Aljurf M; Arai Y; Bacher U; Badar T; Badawy SM; Ballen K; Battiwalla M; Beitinjaneh A; Bejanyan N; Bhatt VR; Brown VI; Martino R; Cahn JY; Castillo P; Cerny J; Chhabra S; Copelan E; Daly A; Dholaria B; Diaz Perez MA; Freytes CO; Grunwald MR; Hashmi S; Hildebrandt GC; Jamy O; Joseph J; Kanakry CG; Khera N; Krem MM; Kuwatsuka Y; Lazarus HM; Lekakis LJ; Liu H; Modi D; Munshi PN; Mussetti A; Palmisiano N; Patel SS; Rizzieri DA; Seo S; Shah MV; Sharma A; Sohl M; Solomon SR; Ulrickson M; Ustun C; van der Poel M; Verdonck LF; Wagner JL; Wang T; Wirk B; Zeidan A; Litzow M; Kebriaei P; Hourigan CS; Weisdorf DJ; Saber W; Kharfan-Dabaja MA
Blood Adv; 2023 Nov; 7(22):7007-7016. PubMed ID: 37792849
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
Lu Y; Sun RJ; Zhang JP; Xu F; Du ZC; Tong GL; Wang Y; Lu DP
Leuk Lymphoma; 2022 Dec; 63(13):3092-3099. PubMed ID: 36067510
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Bashir Q; Milton DR; Popat UR; Kebriaei P; Hosing C; Khouri IF; Rezvani K; Nieto Y; Oran B; Srour SA; Saini NY; Olson AL; Ahmed S; Al-Atrash G; Rondon G; Konopleva MY; Champlin RE; Shpall EJ; Qazilbash MH; Pemmaraju N
Bone Marrow Transplant; 2022 Jan; 57(1):51-56. PubMed ID: 34629467
[TBL] [Abstract][Full Text] [Related]
7. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
[TBL] [Abstract][Full Text] [Related]
8. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis.
Kharfan-Dabaja MA; Reljic T; Murthy HS; Ayala E; Kumar A
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):703-709.e1. PubMed ID: 30145196
[TBL] [Abstract][Full Text] [Related]
11. Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.
Konuma T; Kondo T; Mizuno S; Doki N; Aoki J; Fukuda T; Tanaka M; Sawa M; Katayama Y; Uchida N; Ozawa Y; Morishige S; Matsuoka KI; Ichinohe T; Onizuka M; Kanda J; Atsuta Y; Yanada M;
Biol Blood Marrow Transplant; 2020 Mar; 26(3):463-471. PubMed ID: 31562960
[TBL] [Abstract][Full Text] [Related]
12. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.
Ustun C; Kim S; Chen M; Beitinjaneh AM; Brown VI; Dahi PB; Daly A; Diaz MA; Freytes CO; Ganguly S; Hashmi S; Hildebrandt GC; Lazarus HM; Nishihori T; Olsson RF; Page KM; Papanicolaou G; Saad A; Seo S; William BM; Wingard JR; Wirk B; Yared JA; Perales MA; Auletta JJ; Komanduri KV; Lindemans CA; Riches ML
Blood Adv; 2019 Sep; 3(17):2525-2536. PubMed ID: 31471322
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
14. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Rotz SJ; Hamilton BK; Wei W; Ahmed I; Winston SA; Ballard S; Bernard RJ; Carpenter P; Farhadfar N; Ferraro C; Friend BD; Gloude NJ; Hayashi RJ; Hoyle K; Jenssen K; Koo J; Lee CJ; Mariano L; Nawabit R; Ngwube A; Lalefar N; Phelan R; Perkins L; Rao A; Rayes A; Sandheinrich T; Stafford L; Tomlinson K; Whiteside S; Wiedl C; Myers K
Transplant Cell Ther; 2024 May; 30(5):534.e1-534.e13. PubMed ID: 38342136
[TBL] [Abstract][Full Text] [Related]
15. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.
Hayden PJ; Iacobelli S; Pérez-Simón JA; van Biezen A; Minnema M; Niittyvuopio R; Schönland S; Meijer E; Blaise D; Milpied N; Márquez-Malaver FJ; Veelken JH; Maertens J; Michallet M; Cammenga J; N'Guyen S; Niederwieser D; Hunault-Berger M; Bourhis JH; Passweg J; Bermudez A; Chalandon Y; Yakoub-Agha I; Garderet L; Kröger N
Eur J Haematol; 2020 Mar; 104(3):181-189. PubMed ID: 31737951
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
[TBL] [Abstract][Full Text] [Related]
19. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
